Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Neurourology and Urodynamics
|
September 28, 2020
Overactive bladder medication: Persistence, drug switching, and reinitiation
Takeshi Soda, Yu Tashiro, Shuhei Koike, et al.
IJU Case Reports
|
January 4, 2024
A case of renal cell carcinoma with antiphospholipid syndrome treated by robot-assisted partial nephrectomy
Yu Tashiro, Satoshi Ishitoya, Ryo Yamamoto, et al.
IJU Case Reports
|
March 4, 2025
A successful case of urinary rediversion from a complicated cutaneous ureterostomy to a new ileal conduit
Yu Tashiro, Mami Yamazaki, Yasuaki Katsunaga, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
April 3, 2021
Long-term clinical outcomes of external beam radiation therapy for oligometastatic prostate cancer: A combination of prostate-targeted treatment and metastasis-directed therapy
Rihito Aizawa, Kenji Takayama, Kiyonao Nakamura, et al.
International Journal of Clinical Oncology
|
August 17, 2024
A retrospective study of prognostic factors and prostate-specific antigen dynamics in Japanese patients with metastatic hormone-sensitive prostate cancer who received combined androgen blockade therapy with bicalutamide
Yu Tashiro, Shusuke Akamatsu, Kentaro Ueno, et al.
Cancer Medicine
|
May 1, 2021
Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort
Katsuhiro Ito, Takashi Kobayashi, Takahiro Kojima, et al.
International Journal of Clinical Oncology
|
July 19, 2024
A novel prognostic model of de novo metastatic hormone-sensitive prostate cancer to optimize treatment intensity
Hiroshi Fujiwara, Masashi Kubota, Yu Hidaka, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
September 21, 2021
Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab
Minoru Kato, Takashi Kobayashi, Yoshiyuki Matsui, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Neurourology and Urodynamics
|
September 28, 2020
Overactive bladder medication: Persistence, drug switching, and reinitiation
Takeshi Soda, Yu Tashiro, Shuhei Koike, et al.
IJU Case Reports
|
January 4, 2024
A case of renal cell carcinoma with antiphospholipid syndrome treated by robot-assisted partial nephrectomy
Yu Tashiro, Satoshi Ishitoya, Ryo Yamamoto, et al.
IJU Case Reports
|
March 4, 2025
A successful case of urinary rediversion from a complicated cutaneous ureterostomy to a new ileal conduit
Yu Tashiro, Mami Yamazaki, Yasuaki Katsunaga, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
April 3, 2021
Long-term clinical outcomes of external beam radiation therapy for oligometastatic prostate cancer: A combination of prostate-targeted treatment and metastasis-directed therapy
Rihito Aizawa, Kenji Takayama, Kiyonao Nakamura, et al.
International Journal of Clinical Oncology
|
August 17, 2024
A retrospective study of prognostic factors and prostate-specific antigen dynamics in Japanese patients with metastatic hormone-sensitive prostate cancer who received combined androgen blockade therapy with bicalutamide
Yu Tashiro, Shusuke Akamatsu, Kentaro Ueno, et al.
Cancer Medicine
|
May 1, 2021
Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort
Katsuhiro Ito, Takashi Kobayashi, Takahiro Kojima, et al.
International Journal of Clinical Oncology
|
July 19, 2024
A novel prognostic model of de novo metastatic hormone-sensitive prostate cancer to optimize treatment intensity
Hiroshi Fujiwara, Masashi Kubota, Yu Hidaka, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
September 21, 2021
Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab
Minoru Kato, Takashi Kobayashi, Yoshiyuki Matsui, et al.
Page
of 1